Investing

This Dividend King Is the Safest Dow Stock to Buy and Hold for 20 Years

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) stands out as a candidate for multi-decade portfolios because it pairs a AAA credit rating with 64 consecutive years of dividend increases, a combination almost no other public company in the world…

By Alex Sirois
Published June 4, 2026, 10:12am ET · 3 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© JHVEPhoto / iStock Editorial via Getty Images

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) stands out as a candidate for multi-decade portfolios because it pairs a AAA credit rating with 64 consecutive years of dividend increases, a combination almost no other public company in the world can match.

For a retirement-focused investor who is tired of watching a portfolio bounce on every headline, this is the rare name often considered for a permanent portfolio slot. The case rests on three pillars: durability, income, and the ability to keep paying you through every kind of market.

Pillar 1: A Business Built to Outlast Cycles

Healthcare demand does not move with the business cycle. People do not choose when they get sick, which means demand for life-saving drugs and medical devices stays constant regardless of what Wall Street is doing on any given day. After the Kenvue spinoff, Johnson & Johnson is a pure-play Innovative Medicine and MedTech company, with revenue spread across six priority areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision.

The numbers behind that durability are unusual. Q1 2026 revenue came in at $24.062 billion, up 9.9% year over year, with adjusted EPS of $2.70 beating consensus for the fourth consecutive quarter. Operating margin sits at 27.4% and return on equity at 26.4%. The stock’s beta of 0.263 tells you exactly how it behaves when the market panics: barely.

Pillar 2: Income That Compounds Without Drama

In April, the board approved a 3.1% dividend increase to $1.34 per share, extending the streak to 64 consecutive years. The current annualized dividend of $5.20 works out to a 2.33% yield, and the company generated $19.7 billion in free cash flow in full-year 2025 to back it.

The growth pattern matters more than the headline yield. Quarterly payouts have risen from $1.01 in Q1 2021 to $1.34 in Q2 2026, with no cuts through the 2008 financial crisis, the 2020 pandemic, or any recession in between. That is what reliable compounding looks like in practice.

Pillar 3: Surviving What Breaks Other Stocks

Cycle survival comes from balance sheet strength and pipeline depth. Johnson & Johnson is one of only two U.S. public companies with a AAA credit rating, higher than the U.S. government itself. The pipeline keeps producing: DARZALEX grew 22.5%, CARVYKTI grew 62.1%, and TREMFYA grew 68.3% in Q1 2026. Management raised 2026 guidance to $100.3B-$101.3B in revenue with a stated path to double-digit growth by end of decade.

The Scenario Where It Lags

JNJ will underperform during risk-on rallies when speculative growth names dominate. The current biosimilar erosion of STELARA, which fell 59.7% in Q1 2026 to $656 million, is a real headwind. That does not change the forever thesis because TREMFYA, DARZALEX, and CARVYKTI are already absorbing the share. Patent cliffs are a recurring event for Johnson & Johnson, and the company has survived every previous one by replacing the lost revenue with new approvals. CEO Joaquin Duato called 2025 a “catapult year” for that exact reason.

For long-term holders, the framework is straightforward: collect the dividends, reinvest them, and let compounding do the work.

Contact [email protected] for any questions or corrections.

1INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE

Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org).2The probability of a member receiving $3,000 is 0.028%. If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Members must fund their account with a minimum of $50.00 to qualify. The probability percentage is subject to decrease. Members are only eligible for the Stock Award promotion upon opening their first brokerage account; subsequent cash brokerage accounts are ineligible for the promo, including for members with multiple accounts.

3Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees.

4There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event.
Alex Sirois

Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.
Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.
At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.

All articles →